Indian firm Lupin has entered into a strategic partnership with Yabao Pharmaceutical Co, to meet the growing demand for quality drugs with paediatric formulations in the Chinese markets.

The demand for high quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures. The latest Chinese pediatric pharmaceutical market report indicates that the market for pediatric drugs in China is expected to reach 210 billion CNY ($33 billion) in 2021, growing at a rate of 9.23%.

Dr Fabrice Egros, President - Corporate Development and Growth Markets, Lupin said, “In addition to marketing our pediatric products in the Chinese market, we intend to expand our collaboration in other strategic therapeutics areas such as cardio- metabolic, central nervous system and gastro-enterology.”
 
Wei Ren, President, Yabao said, “Yabao strives to develop its pediatric pipeline to address the urgent unmet needs in the market and to serve the pediatric patients. Moreover, Yabao also looks forward to expanding the collaboration with Lupin in other areas.”